HER2+ Non Small Cell Lung Cancer Epidemiology

Key Highlights

• According to Auliac et al. (2019), in France in non-small cell lung cancers (NSCLCs), HER2 mutation is a rare event, occurring in approximately 1% of the overall lung cancer population. This rate increases to 4.8% in EGFR wild-type lung adenocarcinoma resection specimens. 
• As per the study conducted by Ninomiya et al. (2019), in Japan, out of 1,126 tumors screened tumors, 34 (3.0%) were IHC3þ, and 34 (3.0%) were IHC2þ/ FISHþ. Among the 724 epidermal growth factor receptor wild-type tumors, 21 (2.9%) were HER2-mutant tumors, including A775-G776insYVMA (n=15). Female patients had HER2-mutant tumors more frequently, whereas both IHC3þ and IHC2þ/FISHþ tumors were detected more often in male subjects and smokers. Patients with an HER2-aberrant tumor had a significantly worse prognosis than those with epidermal growth factor receptor-positive and anaplastic lymphoma kinase-positive tumors, possibly due to the low proportion that received HER2-targeted therapies (n=15 [26%]) and low response rates of 0% and 14% in patients with HER2-overexpressing and HER2-mutant tumors, respectively. 
• HER2+ Non-Small Cell Lung Cancer epidemiology is segmented as Total Incident Cases of Non-Small Cell Lung Cancer, Total Incident cases of Non-Small Cell Lung Cancer patients by Histology, Total Diagnosed cases of Non-Small Cell Lung Cancer patients by Stages, Total Non-Small Cell Lung Cancer cases of patients by HER2-positive mutation, and Total Treated cases of Non-Small Cell Lung Cancer patients by Line of Therapies] in the HER2+ Non-Small Cell Lung Cancer market report.

Request for unlock CAGR of HER2+ Non-Small Cell Lung Cancer Epidemiology

DelveInsight's ‘HER2+ Non-Small Cell Lung Cancer Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted HER2+ Non-Small Cell Lung Cancer epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

 

Study Period: 2021-2034

 

HER2+ Non-Small Cell Lung Cancer Market Disease Understanding

The DelveInsight’s HER2+ Non-Small Cell Lung Cancer epidemiology report gives a thorough understanding of HER2+ Non-Small Cell Lung Cancer (HER2+ NSCLC) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas.

 

The human epidermal growth factor receptor (HER) family of receptors plays a central role in the pathogenesis of several human cancers. They regulate cell growth, survival, and differentiation and participate in cellular proliferation and differentiation. The family is made up of four main members: HER-1, HER-2, HER-3, and HER-4, also called ErbB1, ErbB2, ErbB3, and ErbB4, respectively. 

 

The HER2 receptor (previously called HER2/Neu) is a transmembrane glycoprotein with tyrosine kinase activity. It belongs to the epidermal growth factor receptor family (EGFR/ErbB). These receptors are essential in controlling epithelial cell growth and differentiation. HER2 has no known direct activating ligand and may be in an activated state constitutively or become active upon heterodimerization with other family members such as HER1 and HER3.

 

HER2 alterations in NSCLC (Non-Small Cell Lung Cancer) include gene mutations and amplifications. HER2 mutations and HER2 amplifications have been reported in 2–3% and 2–5% of lung adenocarcinomas, respectively. HER2 is found to be amplified in 12–13% of NSCLC cases that have acquired resistance to EGFR-TKIs.

 

HER2+ Non-Small Cell Lung Cancer Diagnosis

Laboratory methods for assessment of HER2 positivity in NSCLC include immunohistochemistry (IHC) for protein overexpression, fluorescent in situ hybridization (FISH) for gene amplification, and next generation sequencing (NGS) for gene mutations.

 

Next generation sequencing (NGS), which allows for simultaneous testing for multiple mutations using one platform and one sample, is emerging as an important method for identification of gene mutations in NSCLC, but single-gene sequencing is still more widely used.

 

HER2+ Non-Small Cell Lung Cancer Epidemiology 

The HER2+ Non-Small Cell Lung Cancer epidemiology section provides insights about historical and current HER2+ Non-Small Cell Lung Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• According to Auliac et al. (2019), in France in non-small cell lung cancers (NSCLCs), HER2 mutation is a rare event, occurring in approximately 1% of the overall lung cancer population. This rate increases to 4.8% in EGFR wild-type lung adenocarcinoma resection specimens. 

 

• As per the study conducted by Ninomiya et al. (2019), in Japan, out of 1,126 tumors screened tumors, 34 (3.0%) were IHC3þ, and 34 (3.0%) were IHC2þ/ FISHþ. Among the 724 epidermal growth factor receptor wild-type tumors, 21 (2.9%) were HER2-mutant tumors, including A775-G776insYVMA (n=15). Female patients had HER2-mutant tumors more frequently, whereas both IHC3þ and IHC2þ/FISHþ tumors were detected more often in male subjects and smokers. Patients with an HER2-aberrant tumor had a significantly worse prognosis than those with epidermal growth factor receptor-positive and anaplastic lymphoma kinase-positive tumors, possibly due to the low proportion that received HER2-targeted therapies (n=15 [26%]) and low response rates of 0% and 14% in patients with HER2-overexpressing and HER2-mutant tumors, respectively. 

 

• The disease epidemiology covered in the report provides historical as well as forecasted HER2+ Non-Small Cell Lung Cancer epidemiology [segmented as Total Incident Cases of Non-Small Cell Lung Cancer, Total Incident cases of Non-Small Cell Lung Cancer patients by Histology, Total Diagnosed cases of Non-Small Cell Lung Cancer patients by Stages, Total Non-Small Cell Lung Cancer cases of patients by HER2-positive mutation, and Total Treated cases of Non-Small Cell Lung Cancer patients by Line of Therapies] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

 

Country Wise- HER2+ Non-Small Cell Lung Cancer Epidemiology

This section provides glimpse of the HER2+ Non-Small Cell Lung Cancer epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

KOL- Views

To keep up with the current HER2+ Non-Small Cell Lung Cancer patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the HER2+ Non-Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Learn how the therapeutic market will evolve and grow in the coming years: HER2+ Non-Small Cell Lung Cancer Market
 

Scope of the HER2+ Non-Small Cell Lung Cancer Epidemiology Report

• The report covers the descriptive overview of HER2+ Non-Small Cell Lung Cancer, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of HER2+ Non-Small Cell Lung Cancer
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Non-Small Cell Lung Cancer, Total Incident cases of Non-Small Cell Lung Cancer patients by Histology, Total Diagnosed cases of Non-Small Cell Lung Cancer patients by Stages, Total Non-Small Cell Lung Cancer cases of patients by HER2-positive mutation, and Total Treated cases of Non-Small Cell Lung Cancer patients by Line of Therapies

 

HER2+ Non-Small Cell Lung Cancer Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence HER2+ Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HER2+ Non-Small Cell Lung Cancer 
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

HER2+ Non-Small Cell Lung Cancer Report Insights

• Patient Population
• Therapeutic Approaches

 

HER2+ Non-Small Cell Lung Cancer Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• HER2+ Non-Small Cell Lung Cancer Epidemiology Segmentation

 

HER2+ Non-Small Cell Lung Cancer Report Assessment

• Disease Understanding
• Current Diagnosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

 

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of HER2+ Non-Small Cell Lung Cancer?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What is the historical HER2+ Non-Small Cell Lung Cancer patient pool in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of HER2+ Non-Small Cell Lung Cancer in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about HER2+ Non-Small Cell Lung Cancer?
• Out of all 7MM countries, which country would have the highest incident population of HER2+ Non-Small Cell Lung Cancer during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the HER2+ Non-Small Cell Lung Cancer Disease market
• To understand the future market competition in the HER2+ Non-Small Cell Lung Cancer Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for HER2+ Non-Small Cell Lung Cancer Disease in the US, Europe (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the HER2+ Non-Small Cell Lung Cancer Disease market
• To understand the future market competition in the HER2+ Non-Small Cell Lung Cancer Disease market

Stay Updated with us for Recent Articles

• The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations
• Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses
• Non-Small Cell Lung Cancer Market: Treatments and Market Forecast
• Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market
• Novel Insights Into The Non-Small Cell Lung Cancer Market
• Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer
• Latest DelveInsight Blogs

Related Infographics of the Report

• BRAF Non-Small Cell Lung Cancer (BRAF+ NSCLC) Market
• ALK Non-Small Cell Lung Cancer (ALK+ NSCLC) Market
• c-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) Market
• EGFR Non-Small Cell Lung Cancer (EGFR+ NSCLC) Market
• PD-L1Non-Small Cell Lung Cancer (PD-L1+ NSCLC) Market